AKT1 and Hyperglycemia: Nevertheless, despite clinically manageable safety profiles being reported, toxic side effects (including hyperglycemia and diarrhea) associated with PI3K/AKT inhibition remain a concern for patients and clinicians, and new approaches to overcome this issue are in demand.